Open AccessPersonalizing treatment in end-stage kidney disease: deciding between haemodiafiltration and haemodialysis based on individualized treatment effect prediction
Author(s) -
Rob C M van Kruijsdijk,
Robin W.M. Vernooij,
Michiel L. Bots,
Sanne A E Peters,
J A N Dorresteijn,
Frank L J Visseren,
Peter J. Blankestijn,
Thomas P. A. Debray,
Michiel L. Bots,
Peter J. Blankestijn,
Bernard Canaud,
Andrew Davenport,
Muriël P.C. Grooteman,
Menso J. Nubé,
Sanne A E Peters,
Marion Moréna,
Francisco Maduell,
Ferran Torres,
Gülay Aşçı,
Francesco Locatelli
Publication year - 2022
Publication title -
clinical kidney journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 40
eISSN - 2048-8513
pISSN - 2048-8505
DOI - 10.1093/ckj/sfac153
Subject(s) - medicine , kidney disease , intensive care medicine , end stage kidney disease , end stage renal disease , creatinine , hemodialysis , diabetes mellitus , endocrinology
Previous studies suggest that haemodiafiltration reduces mortality compared with haemodialysis in patients with end-stage kidney disease (ESKD), but the controversy surrounding its benefits remains and it is unclear to what extent individual patients benefit from haemodiafiltration. This study is aimed to develop and validate a treatment effect prediction model to determine which patients would benefit most from haemodiafiltration compared with haemodialysis in terms of all-cause mortality.